Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP cut its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 25.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,170 shares of the company’s stock after selling 9,163 shares during the period. Two Sigma Investments LP’s holdings in Elanco Animal Health were worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. CoreCap Advisors LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at $29,000. Jones Financial Companies Lllp increased its holdings in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. increased its holdings in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after buying an additional 3,411 shares in the last quarter. MRP Capital Investments LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at $61,000. Finally, Blue Trust Inc. increased its holdings in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after buying an additional 1,894 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on ELAN. Morgan Stanley cut their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. UBS Group cut their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lifted their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a report on Monday, May 19th. Finally, Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Stock Up 2.6%

ELAN stock opened at $14.28 on Wednesday. The stock has a market capitalization of $7.09 billion, a P/E ratio of 35.71, a P/E/G ratio of 2.50 and a beta of 1.67. The firm has a 50-day simple moving average of $11.06 and a 200-day simple moving average of $11.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.34 earnings per share. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.